US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer

发表于 2026-7-25 17:36:04

期刊：Journal of Clinical Oncology

文献作者：Preeti Narayan; Asma Dilawari; Christy Osgood; Zhou Feng; Erik Bloomquist; William F. Pierce; Samina Jafri; Shyam Kalavar; Marina Kondratovich; Prakash Jha; Soma Ghosh; Shenghui Tang; Richard Pazdur; Julia A. Beaver; Laleh Amiri-Kordestani

出版日期：2023-4-10

DOI号：10.1200/jco.22.02447

下载链接：https://ascopubs.org/doi/pdfdirect/10.1200/JCO.22.02447

文献链接：https://doi.org/10.1200/jco.22.02447

当前文献来源于 American Society of Clinical Oncology (ASCO)。

备注信息：

发表于 2026-7-25 17:36:05

: 当前求助已完成，请重新发起求助。
已完结状态的附件将会在24小时内删除。

[ASCO] US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer

已采纳

同分类求助

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[ASCO] US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer 一键复制